Table 5.
Compound (Source) |
Category | Structure | Therapeutic Target | Treatment | Ref. |
---|---|---|---|---|---|
Andrographolide (Andrographis paniculate) |
Diterpenoid | Reduces oxidative stress and inhibits MMP-13 expression. Attenuates cartilage degradation via miR-27-3p/MMP13 signaling. | Anti-oxidant effects. Reduces the degradation of cartilage. | [210,211,212,213,214,215,216,217,218,219,220,221,222] | |
Promotes bone formation by inhibiting NF-κB signaling. | Bone formation | [213,214] | |||
Astaxanthin (Haematococcus pluvialis) |
Tetraterpenoid | Anti-catabolic effects via the activation of Nrf2–ARE signaling. Reduces cartilage degradation via MAPK signaling inhibition. | Antioxidant and anti-inflammatory effects. Attenuates degradation of cartilage | [221,222] | |
Aucubin (Aucuba japonica) |
Iridoid glycoside | Inhibits IL-1β-induced effects. Inhibits iNOS expression and NO production | Anti-inflammatory and antioxidant effects. Prevents OA progression. | [226,227,228,229] | |
Boswellia serrata | 11-Keto-β-boswellic, acetyl-11-keto-β-boswellic acid | Inhibits IL-1β/oncostatin-M-induced effect, decreasing the expression of MMP-9, MMP-13, and COX-2 and reducing the production of NO and PGE2. Inhibits 5-LOX and TNF-α. | Anti-inflammatory and antioxidant effects. | [15,232,233,234] | |
Promotes osteoblast differentiation and suppresses osteoclastogenesis by inhibiting TNF-α and NF-κB signaling. | Bone protection. | [235,236] | |||
Celastrol (Celastrus regelii, Tripterygium wilfordii) |
Triterpenoid | Diminishes the IL-1β-induced catabolic effect, decreasing the expression of MMP-1, MMP-3, MMP-13, iNOS, and COX-2. Reduces cartilage degradation by inhibiting NF-κB signaling and activating SDF-1/CXCR4 signaling. | Anti-inflammatory and anti-catabolic effects. | [238,239,240] | |
Suppresses osteoclastogenesis by inhibiting MAPK and NF-κB signaling. | Bone protection. | [241,242] | |||
Ginsenoside (Panax) |
Terpenoid glycoside | Inhibits the IL-1β-induced effect, decreasing the expression of MMP-1, MMP-13, iNOS, and COX-2; the level of PGE2; promoting the expression of ACAN and Col II. | Anti-inflammatory, anti-apoptotic, antioxidant, and anti-degradative effects. | [244,245,246,247,248,249,250,251,252,253,254] | |
Promotes osteoblast differentiation and suppresses osteoclastogenesis by inhibiting MAPK and NF-κB signaling. | Bone protection | [255,256,257,258,259,260] | |||
Harpagophytum procumbens | Iridoid glycosides | Inhibits IL-1β-induced anti-inflammatory effects, decreasing the expression of IL-6 and MMP-13 via the suppression of c-Fos/AP-1 activity. | Anti-inflammatory effect. | [263] | |
Stimulates osteoblast dif-ferentiation and inhibits osteoclast differentiation. | Bone protection. | [264] |